摘要
Objective: To investigate the effect of metformin combined with DPP-4 inhibitor on the micro-inflammatory status and insulin sensitivity of T2DM patients with metabolic syndrome. Methods: A total of 78 T2DM patients with metabolic syndrome who were treated in the hospital were retrospectively analyzed and divided into the control group (n=41) who received metformin therapy and the combined group (n=37) who received metformin combined with DPP-4 inhibitor therapy, and both groups were treated for 12 weeks. The differences in micro-inflammatory state and insulin sensitivity were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum inflammatory factor contents and peripheral blood insulin sensitivity-related index levels between the two groups before treatment. After 12 weeks of treatment, serum inflammatory factors IL-1, hs-CRP and TNF-α contents of combined group were lower than those of control group;insulin sensitivity indexes FGP, FINS, ISI and HOMA-IR levels were lower than those of control group. Conclusion: metformin combined with DPP-4 inhibitor Sitagliptin can more effectively inhibit the micro-inflammatory state and improve the insulin sensitivity in T2DM patients with metabolic syndrome.
